Post Thumbnail

Presentation of DISSCO results at the upcoming WCO-IOF-ESCEO congress in Paris (past event)

Geneva, March 5, 2019 – We are proud to announce the presentation of the results from the DISSCO (an international, multicentre, double-blind, randomised study of the effect of DIacerein vs celecoxib on Symptoms and Structural Changes in symptomatic knee Osteoarthritis patients as assessed by magnetic resonance imaging) study at the upcoming World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) which will take place on April 4-7 in Palais des Congrès, Paris.

DISSCO is an international, randomized clinical trial which compared the efficacy of diacerein and celecoxib in patients suffering from painful knee osteoarthritis Kellgren-Lawrence grade II-III. Patients were randomized to receive either diacerein 50 mg q.d. during one month and then 50 mg b.i.d., or celecoxib 200 mg b.i.d. The primary objective of DISSCO was to demonstrate the non-inferiority of diacerein versus celecoxib on pain reduction measured with the Western Ontario and McMaster Universities Arthritis Index pain subscale after six months of treatment. The second part of the study, which will evaluate structural changes in patients after two years of therapy, is currently ongoing in Canada.

The poster “DISSCO study: an international, multicenter, double-blind, randomized study on the effect of Diacerein versus Celecoxib on symptoms in knee osteoarthritis patients” by Prof. Jean-Pierre Pelletier and colleagues will present the first results of this study and has been selected for an oral presentation on Saturday 6 at 14:07. The poster will also be presented at the congress the whole day on Friday 5 (poster P170).

Find out more

You are about to leave trbchemedica.com. This link will take you to an external website. Medical practices and regulations can be different from one country to another.

As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.

CONTINUE